ALN-SNCA + Placebo
Phase 1Recruiting 0 views this week 0 watching💤 Quiet
Interest: 36/100
36
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Parkinsons Disease
Conditions
Parkinsons Disease
Trial Timeline
Dec 5, 2025 → Jun 7, 2029
NCT ID
NCT07216066About ALN-SNCA + Placebo
ALN-SNCA + Placebo is a phase 1 stage product being developed by Regeneron Pharmaceuticals for Parkinsons Disease. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07216066. Target conditions include Parkinsons Disease.
What happened to similar drugs?
2 of 3 similar drugs in Parkinsons Disease were approved
Approved (2) Terminated (0) Active (1)
Hype Score Breakdown
Clinical
6
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07216066 | Phase 1 | Recruiting |
Competing Products
5 competing products in Parkinsons Disease
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Mirabegron + Placebo | Astellas Pharma | Approved | 43 |
| Rivastigmine Patch 9.5 cm2 | Novartis | Approved | 43 |
| Prasinezumab + Placebo | Roche | Phase 2 | 39 |
| bemdaneprocel | Bayer | Phase 3 | 44 |
| High dose ANAVEX2-73 + Mid dose ANAVEX2-73 + Placebo oral capsule | Anavex Life Sciences | Phase 2 | 25 |